Clinical trial / 2016
In a randomized crossover challenge, about 14% of patients responsive to gluten withdrawal experienced symptomatic relapse specific to gluten ingestion.
Patients with functional gastrointestinal symptoms followed a 3-week gluten-free diet (GFD), and responsive patients were randomly assigned to 5.6 g/day gluten or placebo for 7 days followed by crossover. Of 134 patients completing the GFD, 101 reported symptomatic improvement (VAS 2.3 ± 1.2 vs. 6.5 ± 2.2, p = 0.001). Among 98 patients undergoing the challenge, 28 experienced symptomatic relapse and reduced quality of life during gluten intake; however, 14 also responded to placebo. Adjusting for the placebo response, approximately 14% of patients responding to gluten withdrawal had a symptomatic relapse during the gluten challenge.
- Study type
- Multicenter randomized double-blind placebo-controlled crossover trial
- Who was studied
- 140 patients with functional gastrointestinal symptoms (134 completed initial phase, 98 challenged)
- What was measured
- Symptom worsening (VAS increase ≥3 cm) during gluten vs. placebo challenge, quality of life, and blood parameters
THE PAPER
Evidence for the Presence of Non-Celiac Gluten Sensitivity in Patients with Functional Gastrointestinal Symptoms: Results from a Multicenter Randomized Double-Blind Placebo-Controlled Gluten Challenge.
Elli L, Tomba C, Branchi F, Roncoroni L, Lombardo V, Bardella MT, Ferretti F, Conte D, Valiante F, Fini L, Forti E, Cannizzaro R, Maiero S, Londoni C, Lauri A, Fornaciari G, Lenoci N, Spagnuolo R, Basilisco G, Somalvico F, Borgatta B, Leandro G, Segato S, Barisani D, Morreale G, Buscarini E. Nutrients, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.